Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 131 articles:
HTML format
Text format



Single Articles


    January 2018
  1. AGAH E, Zardoui A, Saghazadeh A, Ahmadi M, et al
    Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0190252.
    PubMed     Text format     Abstract available


  2. WANG C, Klistorner A, Ly L, Barnett MH, et al
    White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.
    PLoS One. 2018;13:e0191131.
    PubMed     Text format     Abstract available


  3. LAVTAR P, Rudolf G, Maver A, Hodzic A, et al
    Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis.
    PLoS One. 2018;13:e0190601.
    PubMed     Text format     Abstract available


  4. BEGGS CB, Giaquinta A, Veroux M, De Marco E, et al
    Mid-term sustained relief from headaches after balloon angioplasty of the internal jugular veins in patients with multiple sclerosis.
    PLoS One. 2018;13:e0191534.
    PubMed     Text format     Abstract available


  5. CALOCER F, Dejardin O, Droulon K, Launoy G, et al
    Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.
    PLoS One. 2018;13:e0191646.
    PubMed     Text format     Abstract available


  6. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Correction: Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2018;13:e0192317.
    PubMed     Text format     Abstract available


  7. DE FLON P, Soderstrom L, Laurell K, Dring A, et al
    Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.
    PLoS One. 2018;13:e0192516.
    PubMed     Text format     Abstract available


  8. HASSANI A, Corboy JR, Al-Salam S, Khan G, et al
    Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.
    PLoS One. 2018;13:e0192109.
    PubMed     Text format     Abstract available


  9. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility.
    PLoS One. 2018;13:e0190043.
    PubMed     Text format     Abstract available


  10. DENNISON L, Brown M, Kirby S, Galea I, et al
    Do people with multiple sclerosis want to know their prognosis? A UK nationwide study.
    PLoS One. 2018;13:e0193407.
    PubMed     Text format     Abstract available


  11. KHAN A, Kamran S, Ponirakis G, Akhtar N, et al
    Peripheral neuropathy in patients with multiple sclerosis.
    PLoS One. 2018;13:e0193270.
    PubMed     Text format     Abstract available


  12. BAGNATO F, Hametner S, Boyd E, Endmayr V, et al
    Untangling the R2* contrast in multiple sclerosis: A combined MRI-histology study at 7.0 Tesla.
    PLoS One. 2018;13:e0193839.
    PubMed     Text format     Abstract available


  13. NARDIN C, Latarche C, Soudant M, Dahan C, et al
    Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.
    PLoS One. 2018;13:e0194115.
    PubMed     Text format     Abstract available


  14. NOVAKOVA L, Axelsson M, Malmestrom C, Imberg H, et al
    Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
    PLoS One. 2018;13:e0194828.
    PubMed     Text format     Abstract available


  15. KOZIARSKA D, Krol J, Nocon D, Kubaszewski P, et al
    Prevalence and factors leading to unemployment in MS (multiple sclerosis) patients undergoing immunomodulatory treatment in Poland.
    PLoS One. 2018;13:e0194117.
    PubMed     Text format     Abstract available


  16. DE SANTIAGO L, Sanchez-Morla E, Blanco R, Miguel JM, et al
    Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0194964.
    PubMed     Text format     Abstract available


  17. CIURLEO R, Bonanno L, De Salvo S, Romeo L, et al
    Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study.
    PLoS One. 2018;13:e0196006.
    PubMed     Text format     Abstract available


  18. SANCHEZ-DALMAU B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, et al
    Predictors of vision impairment in Multiple Sclerosis.
    PLoS One. 2018;13:e0195856.
    PubMed     Text format     Abstract available


  19. KLISTORNER A, Wang C, Yiannikas C, Parratt J, et al
    Diffusivity in the core of chronic multiple sclerosis lesions.
    PLoS One. 2018;13:e0194142.
    PubMed     Text format     Abstract available


  20. CHROBOK NL, Bol JGJM, Jongenelen CA, Breve JJP, et al
    Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    PLoS One. 2018;13:e0196433.
    PubMed     Text format     Abstract available


  21. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Schuster T, et al
    Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.
    PLoS One. 2018;13:e0196244.
    PubMed     Text format     Abstract available



  22. Correction: Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0196928.
    PubMed     Text format     Abstract available


  23. STORM FA, Nair KPS, Clarke AJ, Van der Meulen JM, et al
    Free-living and laboratory gait characteristics in patients with multiple sclerosis.
    PLoS One. 2018;13:e0196463.
    PubMed     Text format     Abstract available


  24. FERNANDEZ O, Izquierdo G, Fernandez V, Leyva L, et al
    Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
    PLoS One. 2018;13:e0195891.
    PubMed     Text format     Abstract available


  25. SCOTTI B, Disanto G, Sacco R, Guigli M, et al
    Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
    PLoS One. 2018;13:e0197415.
    PubMed     Text format     Abstract available


  26. MARCK CH, De Livera AM, Brown CR, Neate SL, et al
    Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up.
    PLoS One. 2018;13:e0197759.
    PubMed     Text format     Abstract available


  27. POTTGEN J, Rose A, van de Vis W, Engelbrecht J, et al
    Sexual dysfunctions in MS in relation to neuropsychiatric aspects and its psychological treatment: A scoping review.
    PLoS One. 2018;13:e0193381.
    PubMed     Text format     Abstract available


  28. ADUSUMILLI G, Lancia S, Levasseur VA, Amblee V, et al
    Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis.
    PLoS One. 2018;13:e0198178.
    PubMed     Text format     Abstract available


  29. MAIA DINIZ I, Guerra AA Junior, Lovato Pires de Lemos L, Souza KM, et al
    The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.
    PLoS One. 2018;13:e0199446.
    PubMed     Text format     Abstract available


  30. PARKER HARP CR, Archambault AS, Sim J, Shlomchik MJ, et al
    B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis.
    PLoS One. 2018;13:e0199694.
    PubMed     Text format     Abstract available


  31. RAHIMI F, Rasekh HR, Abbasian E, Peiravian F, et al
    Patient preferences for Interferon-beta in Iran: A discrete choice experiment.
    PLoS One. 2018;13:e0193090.
    PubMed     Text format     Abstract available


  32. GIOVANNETTI AM, Borreani C, Bianchi E, Giordano A, et al
    Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study.
    PLoS One. 2018;13:e0200532.
    PubMed     Text format     Abstract available


  33. KODA T, Namba A, Nakatsuji Y, Niino M, et al
    Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    PLoS One. 2018;13:e0193986.
    PubMed     Text format     Abstract available


  34. WUERFEL E, Weddige A, Hagmayer Y, Jacob R, et al
    Cognitive deficits including executive functioning in relation to clinical parameters in paediatric MS patients.
    PLoS One. 2018;13:e0194873.
    PubMed     Text format     Abstract available


  35. KANG Y, Schlyer D, Kaunzner UW, Kuceyeski A, et al
    Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.
    PLoS One. 2018;13:e0201289.
    PubMed     Text format     Abstract available


  36. MARTIN NA, Nawrocki A, Molnar V, Elkjaer ML, et al
    Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.
    PLoS One. 2018;13:e0202530.
    PubMed     Text format     Abstract available


  37. MOKHTARZADEH KHANGHAHI A, Satarian L, Deng W, Baharvand H, et al
    In vivo conversion of astrocytes into oligodendrocyte lineage cells with transcription factor Sox10; Promise for myelin repair in multiple sclerosis.
    PLoS One. 2018;13:e0203785.
    PubMed     Text format     Abstract available


  38. CHAWLA S, Kister I, Sinnecker T, Wuerfel J, et al
    Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging.
    PLoS One. 2018;13:e0202918.
    PubMed     Text format     Abstract available


  39. LASO-GARCIA F, Ramos-Cejudo J, Carrillo-Salinas FJ, Otero-Ortega L, et al
    Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.
    PLoS One. 2018;13:e0202590.
    PubMed     Text format     Abstract available


  40. GRACIA F, Larreategui M, Rodriguez G, Benzadon A, et al
    Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life.
    PLoS One. 2018;13:e0204681.
    PubMed     Text format     Abstract available


  41. SVOLGAARD O, Andersen KW, Bauer C, Madsen KH, et al
    Cerebellar and premotor activity during a non-fatiguing grip task reflects motor fatigue in relapsing-remitting multiple sclerosis.
    PLoS One. 2018;13:e0201162.
    PubMed     Text format     Abstract available


  42. NOCITI V, Santoro M, Quaranta D, Losavio FA, et al
    BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression.
    PLoS One. 2018;13:e0206140.
    PubMed     Text format     Abstract available


  43. SCHEIDLER AM, Kinnett-Hopkins D, Learmonth YC, Motl R, et al
    Targeted ballet program mitigates ataxia and improves balance in females with mild-to-moderate multiple sclerosis.
    PLoS One. 2018;13:e0205382.
    PubMed     Text format     Abstract available


  44. RHEAD B, Brorson IS, Berge T, Adams C, et al
    Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.
    PLoS One. 2018;13:e0206511.
    PubMed     Text format     Abstract available


  45. CHU R, Kim G, Tauhid S, Khalid F, et al
    Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
    PLoS One. 2018;13:e0206939.
    PubMed     Text format     Abstract available


  46. GIORDANO A, Liethmann K, Kopke S, Poettgen J, et al
    Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey.
    PLoS One. 2018;13:e0208004.
    PubMed     Text format     Abstract available


  47. PAWLITZKI M, Sweeney-Reed CM, Meuth SG, Reinhold D, et al
    CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.
    PLoS One. 2018;13:e0207726.
    PubMed     Text format     Abstract available


    January 2017
  48. MOCCIA M, Palladino R, Lanzillo R, Carotenuto A, et al
    Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.
    PLoS One. 2017;12:e0169489.
    PubMed     Text format     Abstract available


  49. BROCHET B, Deloire MS, Perez P, Loock T, et al
    Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
    PLoS One. 2017;12:e0168834.
    PubMed     Text format     Abstract available


  50. LIBERTINOVA J, Meluzinova E, Tomek A, Horakova D, et al
    Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta.
    PLoS One. 2017;12:e0169957.
    PubMed     Text format     Abstract available


  51. RAFFEL J, Gafson AR, Dahdaleh S, Malik O, et al
    Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    PLoS One. 2017;12:e0169546.
    PubMed     Text format     Abstract available


  52. KAVALIUNAS A, Manouchehrinia A, Danylaite Karrenbauer V, Gyllensten H, et al
    Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    PLoS One. 2017;12:e0169460.
    PubMed     Text format     Abstract available


  53. HURTADO-GUERRERO I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, et al
    Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNss in Multiple Sclerosis Patients According to the Therapeutic Response to IFNss.
    PLoS One. 2017;12:e0170031.
    PubMed     Text format     Abstract available


  54. UECKER FC, Olze H, Kunte H, Gerz C, et al
    Longitudinal Testing of Olfactory and Gustatory Function in Patients with Multiple Sclerosis.
    PLoS One. 2017;12:e0170492.
    PubMed     Text format     Abstract available


  55. ZOU L, Wang H, Xiao Z, Fang Q, et al
    Tai chi for health benefits in patients with multiple sclerosis: A systematic review.
    PLoS One. 2017;12:e0170212.
    PubMed     Text format     Abstract available


  56. MOON Y, McGinnis RS, Seagers K, Motl RW, et al
    Monitoring gait in multiple sclerosis with novel wearable motion sensors.
    PLoS One. 2017;12:e0171346.
    PubMed     Text format     Abstract available


  57. LINK J, Ramanujam R, Auer M, Ryner M, et al
    Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    PLoS One. 2017;12:e0170395.
    PubMed     Text format     Abstract available


  58. MORANDI E, Tanasescu R, Tarlinton RE, Constantinescu CS, et al
    The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0172415.
    PubMed     Text format     Abstract available


  59. BEHBEHANI R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, et al
    Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    PLoS One. 2017;12:e0172120.
    PubMed     Text format     Abstract available


  60. FAIZY TD, Thaler C, Ceyrowski T, Broocks G, et al
    Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.
    PLoS One. 2017;12:e0172923.
    PubMed     Text format     Abstract available


  61. KOMEGAE EN, Souza TA, Grund LZ, Lima C, et al
    Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0171796.
    PubMed     Text format     Abstract available


  62. WENDEBOURG MJ, Heesen C, Finlayson M, Meyer B, et al
    Patient education for people with multiple sclerosis-associated fatigue: A systematic review.
    PLoS One. 2017;12:e0173025.
    PubMed     Text format     Abstract available


  63. MULS N, Nasr Z, Dang HA, Sindic C, et al
    IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.
    PLoS One. 2017;12:e0173780.
    PubMed     Text format     Abstract available


  64. HEGEN H, Auer M, Bsteh G, Di Pauli F, et al
    Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
    PLoS One. 2017;12:e0174005.
    PubMed     Text format     Abstract available


  65. AYUSO T, Aznar P, Soriano L, Olaskoaga A, et al
    Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis.
    PLoS One. 2017;12:e0174726.
    PubMed     Text format     Abstract available


  66. GIESS RM, Pfuhl C, Behrens JR, Rasche L, et al
    Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.
    PLoS One. 2017;12:e0175279.
    PubMed     Text format     Abstract available


  67. DOBRAKOWSKI P, Bogocz M, Cholewa K, Rajchel M, et al
    Month of birth and level of insolation as risk factors for multiple sclerosis in Poland.
    PLoS One. 2017;12:e0175156.
    PubMed     Text format     Abstract available


  68. ZHAO Y, Healy BC, Rotstein D, Guttmann CR, et al
    Exploration of machine learning techniques in predicting multiple sclerosis disease course.
    PLoS One. 2017;12:e0174866.
    PubMed     Text format     Abstract available


  69. KRAMER J, Tenberge JG, Kleiter I, Gaissmaier W, et al
    Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    PLoS One. 2017;12:e0174858.
    PubMed     Text format     Abstract available


  70. SHARMA S, Zhang Y
    Fourier transform power spectrum is a potential measure of tissue alignment in standard MRI: A multiple sclerosis study.
    PLoS One. 2017;12:e0175979.
    PubMed     Text format     Abstract available


  71. NAVAS-MADRONAL M, Valero-Mut A, Martinez-Zapata MJ, Simon-Talero MJ, et al
    Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
    PLoS One. 2017;12:e0175538.
    PubMed     Text format     Abstract available


  72. SCHNEIDER R, Bellenberg B, Hoepner R, Kolb EM, et al
    Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    PLoS One. 2017;12:e0176415.
    PubMed     Text format     Abstract available


  73. INGLESE M, Petracca M, Mormina E, Achiron A, et al
    Cerebellar volume as imaging outcome in progressive multiple sclerosis.
    PLoS One. 2017;12:e0176519.
    PubMed     Text format     Abstract available


  74. IZQUIERDO G, Damas F, Paramo MD, Ruiz-Pena JL, et al
    The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    PLoS One. 2017;12:e0176174.
    PubMed     Text format     Abstract available


  75. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2017;12:e0177177.
    PubMed     Text format     Abstract available


  76. MOLLISON D, Sellar R, Bastin M, Mollison D, et al
    The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0177727.
    PubMed     Text format     Abstract available


  77. MCGINNIS RS, Mahadevan N, Moon Y, Seagers K, et al
    A machine learning approach for gait speed estimation using skin-mounted wearable sensors: From healthy controls to individuals with multiple sclerosis.
    PLoS One. 2017;12:e0178366.
    PubMed     Text format     Abstract available


  78. PARDO E, Carcamo C, Uribe-San Martin R, Ciampi E, et al
    Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis.
    PLoS One. 2017;12:e0177472.
    PubMed     Text format     Abstract available


  79. LANDI D, Albanese M, Buttari F, Monteleone F, et al
    Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    PLoS One. 2017;12:e0165415.
    PubMed     Text format     Abstract available


  80. RIGHART R, Schmidt P, Dahnke R, Biberacher V, et al
    Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.
    PLoS One. 2017;12:e0179590.
    PubMed     Text format     Abstract available


  81. BERNITSAS E, Khan O, Razmjou S, Tselis A, et al
    Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.
    PLoS One. 2017;12:e0181431.
    PubMed     Text format     Abstract available


  82. ITOH Y, Voskuhl RR
    Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
    PLoS One. 2017;12:e0181349.
    PubMed     Text format     Abstract available


  83. BSTEH G, Ehling R, Walchhofer LM, Hegen H, et al
    Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.
    PLoS One. 2017;12:e0181458.
    PubMed     Text format     Abstract available


  84. KIM HH, Jeong IH, Hyun JS, Kong BS, et al
    Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance.
    PLoS One. 2017;12:e0181758.
    PubMed     Text format     Abstract available


  85. WURTH S, Kuenz B, Bsteh G, Ehling R, et al
    Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    PLoS One. 2017;12:e0182462.
    PubMed     Text format     Abstract available


  86. MESSINA S, Solaro C, Righini I, Bergamaschi R, et al
    Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
    PLoS One. 2017;12:e0180651.
    PubMed     Text format     Abstract available


  87. ABDELHAK A, Hottenrott T, Mayer C, Hintereder G, et al
    CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.
    PLoS One. 2017;12:e0182647.
    PubMed     Text format     Abstract available


  88. THALER C, Schneider T, Sedlacik J, Kutzner D, et al
    T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis.
    PLoS One. 2017;12:e0183099.
    PubMed     Text format     Abstract available


  89. MODICA CM, Schweser F, Sudyn ML, Bertolino N, et al
    Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0182729.
    PubMed     Text format     Abstract available


  90. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Microstructural analyses of the posterior cerebellar lobules in relapsing-onset multiple sclerosis and their implication in cognitive impairment.
    PLoS One. 2017;12:e0182479.
    PubMed     Text format     Abstract available


  91. CEUNINCK VAN CAPELLE A, Meide HV, Vosman FJH, Visser LH, et al
    A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).
    PLoS One. 2017;12:e0182806.
    PubMed     Text format     Abstract available


  92. PUTHENPARAMPIL M, Federle L, Poggiali D, Miante S, et al
    Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.
    PLoS One. 2017;12:e0183957.
    PubMed     Text format     Abstract available


  93. MASUDA H, Hirano S, Takahashi N, Hatsugano E, et al
    Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder.
    PLoS One. 2017;12:e0184012.
    PubMed     Text format     Abstract available


  94. PARK HY, Park JW, Song HJ, Sohn HS, et al
    The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea.
    PLoS One. 2017;12:e0169463.
    PubMed     Text format     Abstract available


  95. TALMAGE GD, Coppes OJM, Javed A, Bernard J, et al
    Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
    PLoS One. 2017;12:e0173299.
    PubMed     Text format     Abstract available


  96. ZAPRUTKO T, Kopciuch D, Kus K, Merks P, et al
    Affordability of medicines in the European Union.
    PLoS One. 2017;12:e0172753.
    PubMed     Text format     Abstract available


  97. PAUZUOLIS M, Eich T, Burman J
    Quantification of gammadelta T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.
    PLoS One. 2017;12:e0179095.
    PubMed     Text format     Abstract available


  98. CHAMI M, Halmer R, Schnoeder L, Anne Becker K, et al
    Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    PLoS One. 2017;12:e0178622.
    PubMed     Text format     Abstract available


  99. ALSOP J, Medin J, Cornelissen C, Vormfelde SV, et al
    Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
    PLoS One. 2017;12:e0173353.
    PubMed     Text format     Abstract available


  100. TAKAYASU L, Suda W, Watanabe E, Fukuda S, et al
    A 3-dimensional mathematical model of microbial proliferation that generates the characteristic cumulative relative abundance distributions in gut microbiomes.
    PLoS One. 2017;12:e0180863.
    PubMed     Text format     Abstract available


  101. JONAS SF, Mbogning C, Hassler S, Broet P, et al
    A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology.
    PLoS One. 2017;12:e0179896.
    PubMed     Text format     Abstract available


  102. KIDD T, Carey N, Mold F, Westwood S, et al
    A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life.
    PLoS One. 2017;12:e0185931.
    PubMed     Text format     Abstract available


  103. FERNANDEZ O, Duran E, Ayuso T, Hernandez L, et al
    Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
    PLoS One. 2017;12:e0185766.
    PubMed     Text format     Abstract available


  104. FAVARETTO A, Lazzarotto A, Riccardi A, Pravato S, et al
    Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis.
    PLoS One. 2017;12:e0185626.
    PubMed     Text format     Abstract available


  105. BESELER C, Vollmer T, Graner M, Yu X, et al
    The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution.
    PLoS One. 2017;12:e0186842.
    PubMed     Text format     Abstract available


  106. RAKNES G, Smabrekke L
    Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.
    PLoS One. 2017;12:e0187423.
    PubMed     Text format     Abstract available


  107. WYBRECHT D, Reuter F, Pariollaud F, Zaaraoui W, et al
    New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study.
    PLoS One. 2017;12:e0184650.
    PubMed     Text format     Abstract available


  108. LIU S, Liu X, Chen S, Xiao Y, et al
    Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
    PLoS One. 2017;12:e0188644.
    PubMed     Text format     Abstract available


  109. MOISSET X, Perie M, Pereira B, Dumont E, et al
    Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
    PLoS One. 2017;12:e0188120.
    PubMed     Text format     Abstract available


  110. GROBELNY A, Behrens JR, Mertens S, Otte K, et al
    Maximum walking speed in multiple sclerosis assessed with visual perceptive computing.
    PLoS One. 2017;12:e0189281.
    PubMed     Text format     Abstract available


  111. WEN J, Yablonskiy DA, Salter A, Cross AH, et al
    Limbic system damage in MS: MRI assessment and correlations with clinical testing.
    PLoS One. 2017;12:e0187915.
    PubMed     Text format     Abstract available


  112. CHEN Y, Zhen W, Guo T, Zhao Y, et al
    Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination.
    PLoS One. 2017;12:e0189380.
    PubMed     Text format     Abstract available


    January 2016
  113. OBERT D, Helms G, Sattler MB, Jung K, et al
    Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    PLoS One. 2016;11:e0162583.
    PubMed     Text format     Abstract available


  114. SOLARO C, Trabucco E, Signori A, Martinelli V, et al
    Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.
    PLoS One. 2016;11:e0160261.
    PubMed     Text format     Abstract available


  115. TSIVGOULIS G, Katsanos AH, Mavridis D, Grigoriadis N, et al
    The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
    PLoS One. 2016;11:e0163296.
    PubMed     Text format     Abstract available


  116. MONTI MC, Guido D, Montomoli C, Sardu C, et al
    Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia.
    PLoS One. 2016;11:e0163313.
    PubMed     Text format     Abstract available


  117. JERNAS L, Wencel J, Wiak A, Bieniek M, et al
    Risk Factors for Poor Adherence to Betaferon(R) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
    PLoS One. 2016;11:e0157950.
    PubMed     Text format     Abstract available


  118. KAUSHIK DK, Yong HY, Hahn JN, Silva C, et al
    Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.
    PLoS One. 2016;11:e0163802.
    PubMed     Text format     Abstract available


  119. RIEMANN-LORENZ K, Eilers M, von Geldern G, Schulz KH, et al
    Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program.
    PLoS One. 2016;11:e0165246.
    PubMed     Text format     Abstract available


  120. KALRON A, Givon U, Frid L, Dolev M, et al
    Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis.
    PLoS One. 2016;11:e0164467.
    PubMed     Text format     Abstract available


  121. HAJIEBRAHIMI M, Montgomery S, Burkill S, Bahmanyar S, et al
    Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0165027.
    PubMed     Text format     Abstract available


  122. KREMER IE, Evers SM, Jongen PJ, van der Weijden T, et al
    Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.
    PLoS One. 2016;11:e0164862.
    PubMed     Text format     Abstract available


  123. BACHELET D, Hassler S, Mbogning C, Link J, et al
    Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    PLoS One. 2016;11:e0162752.
    PubMed     Text format     Abstract available


  124. ALROUGHANI R, Akhtar S, Ahmed S, Behbehani R, et al
    Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
    PLoS One. 2016;11:e0165846.
    PubMed     Text format     Abstract available


  125. DOBSON R, Ramagopalan S, Topping J, Smith P, et al
    A Risk Score for Predicting Multiple Sclerosis.
    PLoS One. 2016;11:e0164992.
    PubMed     Text format     Abstract available


  126. ZHANG L, Wang L, Tian P, Tian S, et al
    Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.
    PLoS One. 2016;11:e0165543.
    PubMed     Text format     Abstract available


  127. MARTIN P, McGovern A, Massey J, Schoenfelder S, et al
    Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C.
    PLoS One. 2016;11:e0166923.
    PubMed     Text format     Abstract available


  128. JOHNSON TW, Wu Y, Nathoo N, Rogers JA, et al
    Gray Matter Hypoxia in the Brain of the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0167196.
    PubMed     Text format     Abstract available


  129. PIVOT D, Debouverie M, Grzebyk M, Brassat D, et al
    Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.
    PLoS One. 2016;11:e0167556.
    PubMed     Text format     Abstract available


  130. PROSPERINI L, de Rossi N, Scarpazza C, Moiola L, et al
    Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    PLoS One. 2016;11:e0168376.
    PubMed     Text format     Abstract available


  131. BLOCK VA, Pitsch E, Tahir P, Cree BA, et al
    Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
    PLoS One. 2016;11:e0154335.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: